1. Home
  2. CERO vs SPHL Comparison

CERO vs SPHL Comparison

Compare CERO & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • SPHL
  • Stock Information
  • Founded
  • CERO 2017
  • SPHL 2002
  • Country
  • CERO United States
  • SPHL Singapore
  • Employees
  • CERO N/A
  • SPHL N/A
  • Industry
  • CERO
  • SPHL Homebuilding
  • Sector
  • CERO
  • SPHL Consumer Discretionary
  • Exchange
  • CERO Nasdaq
  • SPHL Nasdaq
  • Market Cap
  • CERO 6.1M
  • SPHL 4.9M
  • IPO Year
  • CERO N/A
  • SPHL 2024
  • Fundamental
  • Price
  • CERO $5.39
  • SPHL $0.65
  • Analyst Decision
  • CERO Strong Buy
  • SPHL
  • Analyst Count
  • CERO 2
  • SPHL 0
  • Target Price
  • CERO $45.00
  • SPHL N/A
  • AVG Volume (30 Days)
  • CERO 82.8K
  • SPHL 3.4M
  • Earning Date
  • CERO 11-18-2025
  • SPHL 10-28-2025
  • Dividend Yield
  • CERO N/A
  • SPHL N/A
  • EPS Growth
  • CERO N/A
  • SPHL N/A
  • EPS
  • CERO N/A
  • SPHL N/A
  • Revenue
  • CERO N/A
  • SPHL $5,956,226.00
  • Revenue This Year
  • CERO N/A
  • SPHL N/A
  • Revenue Next Year
  • CERO N/A
  • SPHL N/A
  • P/E Ratio
  • CERO N/A
  • SPHL N/A
  • Revenue Growth
  • CERO N/A
  • SPHL N/A
  • 52 Week Low
  • CERO $4.27
  • SPHL $0.35
  • 52 Week High
  • CERO $895.40
  • SPHL $7.80
  • Technical
  • Relative Strength Index (RSI)
  • CERO 40.84
  • SPHL 63.26
  • Support Level
  • CERO $5.18
  • SPHL $0.52
  • Resistance Level
  • CERO $5.45
  • SPHL $0.85
  • Average True Range (ATR)
  • CERO 0.24
  • SPHL 0.09
  • MACD
  • CERO 0.09
  • SPHL 0.01
  • Stochastic Oscillator
  • CERO 56.96
  • SPHL 59.30

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

Share on Social Networks: